57 results about "Modifying genes" patented technology

The invention discloses a construction method and application of a chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain, the construction method comprises the following steps: carrying out gene modification on sweeteners Thaumatin and Brazzein, optimizing preference codons of chlamydomonas reinhardtii to synthesize CrThaumatin and CrBrazzein encoding genes, cloning the encoding genes into an expression vector pGM6, introducing the recombinant expression vector into a chlamydomonas reinhardtii wild-type chlamydomonas sp. Algal strain, and carrying out high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii-sourced high-sweetness protein variant engineering algal strain of the chlamydomonas reinhardtii. And screening by using a paromomycin resistance marker carried by the expression vector to successfully obtain an engineering algal strain. According to the present invention, the engineering strain is subjected to fermentation production to obtain the dry and stable Chlamydomonas reinhardtii powder rich in the target sweet protein, and the protein purification oral test results show that the sweet taste of the Chlamydomonas reinhardtii powder is 3-5 times of the sweet taste of the natural Thaumatin and Brazzein protein;

The invention discloses application of a lactic acid modified gene ENO1 inhibitor in preparation of a medicine for treating nasopharynx cancer, and relates to the technical field of biological medicines. A head and neck squamous cell carcinoma prognosis model containing seven lactylation related genes is constructed by analyzing a TCGA database, the model can effectively distinguish patient risks, the total lifetime of a high-risk group is remarkably shortened, and a risk score is an independent prognosis factor; the functions of the key gene ENO1 are deeply studied through in-vitro experiments, and experimental results show that silencing of the ENO1 gene in nasopharynx cancer 5-8F cells causes up-regulation of cell pan-lactylation level, up-regulation of MMP2 expression and down-regulation of E-cadherin expression, and migration and invasion ability of tumor cells is significantly enhanced. The prognosis model provided by the invention has an important clinical prediction value, inhibition of ENO1 can promote tumor progression through abnormal lactylation, and a new thought is provided for taking ENO1 as a treatment target.

The present invention addresses the problem of providing a technique capable of haploid induction by enhancing the expression and / or function of a regulatory gene. The problem is solved by the use of a modified plant comprising an introduced or modified H2A.W gene, wherein said introduction or modification enhances the expression and / or function of the H2A.W gene in a germ cell.

The invention discloses a primer group, a kit and a detection system for thalassemia gene detection. In order to more comprehensively and accurately detect point mutation, small insertion, small deletion, gene fusion mutation, large fragment deletion and gene structure variation on a thalassemia core gene and a modified gene in single detection, the invention provides a thalassemia gene detection primer group and a kit. Based on third-generation sequencing platforms such as a single-base nanopore sequencing platform and the like, all point mutation, small insertion, small deletion and gene fusion mutation in the amplification range of the thalassemia core gene and the modified gene can be detected by utilizing the primer group or the kit; and 60 alpha large fragment deletion mutations, 60 beta large fragment deletion mutations and 7 gene structure variations. The method is beneficial to rapid and comprehensive screening of thalassemia, and is high in detection sensitivity and good in accuracy.

An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.

Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.

The invention belongs to the technical field of gene engineering and enzyme engineering, and particularly relates to a high-temperature-resistant phytase mutant as well as a preparation method and application thereof. The 19 , 104 and 305 genes of a phytase gene appA are modified to obtain a plurality of high-temperature-resistant phytase mutants, the heat resistance of the three mutants G19P / G104P / D305R is remarkably superior to that of wild type and traditional phytase, experimental results show that after the phytase mutants are respectively treated for 20 minutes at the high temperature of 80 DEG C, 90 DEG C and 100 DEG C, the residual rates of enzyme activity are respectively 94.6%, 91.8% and 66.5%, and the residual rates of enzyme activity are respectively 94.6%, 91.8% and 66.5%. The phytase can completely tolerate granulation at the high temperature of 80-95 DEG C in the feed industry, and the industrial pain point of insufficient enzyme activity after traditional phytase granulation is greatly solved.

Isolated or purified antisense oligomers, combinations, and cocktails for modifying premRNA splicing or mRNA translation in the SOST gene transcript or a portion thereof to induce downregulation of functional SOST protein production. Isolated or purified antisense oligomers are provided, as needed, for inducing the production of proteins with retained or partially retained introns, truncated proteins, proteins lacking functional regions, or a reduction in the total amount of protein produced.

Disclosed are composition comprising (a) an inducible transgene construct, comprising a sequence encoding an inducible promoter and a sequence encoding a transgene, and (b) a receptor construct, comprising a sequence encoding a constitutive promoter and a sequence encoding an exogenous receptor, wherein, upon integration of the construct of (a) and the construct of (b) into a genomic sequence of a cell, the exogenous reporter is expressed, and wherein the exogenous reporter, upon binding a ligand, transduces an intracellular signal that targets the inducible promoter of (a) to modify gene expression. Methods for introducing compositions into cells and the use of the resultant cells in adoptive cell therapies are also provided.

The present invention relates to a modified CCA gene which encodes a CCA-adding enzyme, which modified CCA gene leads to resistance against a positive-strand RNA virus having a transfer RNA-like structure (TLS). The invention further relates to plants and seeds comprising the modified genes, methods for making and identifying such plants and use of the gene.

This invention discloses the application of chloroquine in improving gene editing efficiency. Specifically, it provides a novel use for chloroquine: enhancing the gene editing efficiency of gene editing reagents on recipient biological materials. The gene editing reagent is a gene editing tool plasmid. No prior art studies have combined chloroquine with gene editing efficiency. The inventors of this invention have discovered that treating recipient biological materials with chloroquine before transfecting them with gene editing reagents can significantly improve gene editing efficiency. This invention is simple to operate, widely applicable, and opens up a new avenue for improving editing efficiency by introducing exogenous small molecules rather than directly modifying gene editing tools.

The invention discloses application of hydroxychloroquine to improvement of gene editing efficiency. The invention provides novel application of hydroxychloroquine, namely application of hydroxychloroquine in improving gene editing efficiency of a gene editing reagent on a receptor biological material. In the prior art, a research of combining hydroxychloroquine and gene editing efficiency is not seen. The inventor of the invention finds that the gene editing efficiency can be remarkably improved by treating a receptor biological material with hydroxychloroquine and then transfecting a gene editing reagent. The method is easy and convenient to operate and wide in applicability, and a new way for improving the editing efficiency is developed by introducing exogenous small molecules instead of directly modifying a gene editing tool. The invention provides a basis for exploring an editing efficiency improvement strategy by adding exogenous molecules instead of modifying an editor mutant.

Provided in the present disclosure is a composition for treating primary hyperoxaluria (PH). The composition provided by the present disclosure comprises a CRISPR-Cas system comprising a nuclease and a guide RNA for modifying a HAO1 gene. Further provided is a method for implementing treatment by administering a HAO1 gene-targeting system or a nucleic acid encoding same to a subject afflicted with a disease associated with primary hyperoxaluria (PH).

The present disclosure relates to the field of biomedicine, and in particular to a preparation method for and a use of an aging animal model. The present disclosure provides a method for preparing an aging animal model, comprising modifying genes in immune cells in an animal body, wherein the modification reduces or eliminates the function or level of Abhd5.

The invention belongs to the field of biological medicine, and relates to a preparation method and application of a metabolic syndrome animal model. The invention provides a preparation method and application of a metabolic syndrome animal model, the preparation method comprises the step of modifying genes in immune cells in an animal body, and the modification reduces or eliminates the function or level of Abhd5 in Treg cells.

The present invention relates to methods of generating one or more transgenic cells using circular single stranded DNA (CiSSD) as a donor template, as well as target genome modification. The methods include transferring one or more DNA polynucleotides into a cell for site-specific nuclease-mediated DNA repair, and selecting one or more cells into which the transferred DNA is introduced in the genome of the cell.

This disclosure provides modified AAV vectors for expressing tripeptidyl peptidase 1 (TPP1) in objects. Some aspects of this disclosure provide modified adeno-associated virus 1 (AAV1) vectors comprising a capsid protein containing a targeting peptide and a nucleic acid molecule containing a sequence encoding a modified AAV genome, said modified AAV genome comprising a replication (rep) gene, a capsid (cap) gene, and a tripeptidyl peptidase 1 (TPP1) transgene.

Disclosed are composition comprising (a) an inducible transgene construct, comprising a sequence encoding an inducible promoter and a sequence encoding a transgene, and (b) a receptor construct, comprising a sequence encoding a constitutive promoter and a sequence encoding an exogenous receptor, wherein, upon integration of the construct of (a) and the construct of (b) into a genomic sequence of a cell, the exogenous reporter is expressed, and wherein the exogenous reporter, upon binding a ligand, transduces an intracellular signal that targets the inducible promoter of (a) to modify gene expression. Methods for introducing compositions into cells and the use of the resultant cells in adoptive cell therapies are also provided.

Provided herein are recombinant adeno-associated virus (rAAV) particles encoding microRNAs targeting the glucocorticoid receptor (GR) pathway, and in particular a microRNA17-92 (miR 17-92) cluster, and genes of interest. The modified genomes of these rAAV particles comprise heterologous nucleic acid sequences encoding microRNA structures. These particles exhibit enhanced transduction efficiencies in mammalian cells. Also provided herein are compositions of nucleic acids encoding the miR 17-92 cluster and nucleic acids encoding a gene of interest. Further provided herein are methods for administering these nucleic acid compositions to enhance transduction efficiencies.

This application relates to the fields of bioengineering and fermentation technology, and discloses a genetically engineered *Escherichia coli* strain that synthesizes L-histidine and its preparation method. The engineered strain uses *Escherichia coli* W3110 as the starting strain and is modified... hisG Gene release from feedback inhibition; knockout ushA and nrdD Genes reduce precursor consumption; inactivation slyA Genes reduce energy waste; heterogeneous integration zwf and gnd Genes and replacement pgi The gene promoter redirects carbon flow to the pentose phosphate pathway, enhancing the supply of key precursors PRPP and reducing agent NADPH; introducing courtE Genes promote product efflux. Combined with an optimized fed-batch fermentation process, this invention effectively solves the problems of insufficient precursor supply, uneven energy distribution, and product inhibition through a systems metabolic engineering strategy, increasing L-histidine yield and sugar-acid conversion rate, making it suitable for industrial production.

Compositions and methods for modifying genomic DNA sequences are provided. The methods produce double-stranded breaks (DSBs) at pre-determined target sites in a genomic DNA sequence, resulting in mutation, insertion, and / or deletion of DNA sequences at the target site(s) in a genome. Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cms1 protein operably linked to a promoter that is operable in the cells of interest. The DNA constructs can be used to direct the modification of genomic DNA at pre-determined genomic loci. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided. Compositions comprise DNA constructs comprising a promoter that is operable in the cells of interest operably linked to nucleotide sequences that encode a mutated Cms1 protein with an abolished ability to produce DSBs, optionally linked to a domain that regulates transcriptional activity. The methods can be used to up-or down-regulate the expression of genes at predetermined genomic loci.

The invention discloses a method for improving gene expression and plant herbicide resistance, and particularly relates to a method for improving the expression level of endogenous polynucleotide or a target gene by modifying upstream and downstream of a transcription start site of the target gene through a genome editing technology and modifying a non-coding region of the gene. Furthermore, the HPPD gene and / or HIS1 gene related to the herbicide resistance of the plant are / is modified by the method to regulate and control, so that the herbicide resistance of the plant is improved.

The present disclosure relates to type II Cas proteins, CRISPR-Cas systems, and various applications thereof. The Type II Cas proteins described in the present disclosure extend the utility of CRISPR-Cas systems in targeting or modifying genes.

The present disclosure provides a composition for treating hemoglobinopathy (e.g. sickle cell anemia, hemophilia, β-thalassemia, etc.). The present composition comprises a nuclease for modifying the BCL11A gene and a CRISPR-Cas system comprising a guide RNA. Also provided is a method for treatment by administering, in a subject with a hemoglobinopathy-related disease, a system that targets the BCL11A gene or a nucleic acid that encodes such a system.

An isolated or purified antisense oligomer and compositions and mixtures for modifying pre-messenger RNA (pre mRNA) splicing or mRNA translation in a SOST gene transcript or part thereof to induce down regulation of functional SOST protein production.

Provided herein are nucleic acids useful as guide nucleic acids (gNAs), e.g., guide ribonucleic acids (gRNAs), in a CRISPR system wherein the guide nucleic acids contain one or more modifications to one or more nucleotides, use of such guide nucleic acids in modifying cells, and other uses wherein CRISPR Cas proteins are utilized.

The invention discloses a method for increasing glutamic acid yield. Modified bacteria that produce L-glutamic acid are provided wherein a heterologous polynucleotide of phosphoketolase (XFP), and one or more of a modification of increased activity of the gluAA1T, icd gene, aceE gene and / or pyc gene, are included in the genome as compared to non-modified bacteria. In addition, methods of increasing the yield of L-glutamic acid using the modified bacteria are also provided.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

he present disclosure describes a genetically modified microbial host cell expressing and secreting a compound of interest, wherein the cell comprises a native gene involved in the regulation of secretion from the cell of the compound of interest with a signal peptide and / or without a signal peptide wherein the native gene has been modified to alter its functionality in the cell whereby the secretion and yield of the compound of interest from the cell is increased compared to a cell where the gene has not been modified.